

Multiple Sclerosis (MS) Drugs-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/M5E21103709MEN.html

Date: February 2018

Pages: 155

Price: US\$ 2,480.00 (Single User License)

ID: M5E21103709MEN

Abstracts

Report Summary

Multiple Sclerosis (MS) Drugs-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Multiple Sclerosis (MS) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Multiple Sclerosis (MS) Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Multiple Sclerosis (MS) Drugs worldwide, with company and product introduction, position in the Multiple Sclerosis (MS) Drugs market Market status and development trend of Multiple Sclerosis (MS) Drugs by types and applications

Cost and profit status of Multiple Sclerosis (MS) Drugs, and marketing status Market growth drivers and challenges

The report segments the global Multiple Sclerosis (MS) Drugs market as:

Global Multiple Sclerosis (MS) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America Europe China

Japan



Rest APAC

Latin America

Global Multiple Sclerosis (MS) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Copaxone (Glatiramer Acetate, Copolymer 1)

Novantrone (Mitoxantrone)

Gilenya (Fingolimod, Fty720)

Aubagio (Teriflunomide)

Tecfidera (Dimethyl Fumarate)

Firategrast (Sb683699, T-0047)

Siponimod (Baf312)

Others

Global Multiple Sclerosis (MS) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

RRMS

SPMS

PPMS

PRMS

Global Multiple Sclerosis (MS) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price and Gross Margin):

Bayer AG

Bayhill Therapeutics

Biogen Idec

Cinnagen

Daiichi Sankyo

Eli Lilly

Fast Forward Llc

Antisense Therapeutics

Apitope

Five Prime Therapeutics

Genmab



Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF MULTIPLE SCLEROSIS (MS) DRUGS

- 1.1 Definition of Multiple Sclerosis (MS) Drugs in This Report
- 1.2 Commercial Types of Multiple Sclerosis (MS) Drugs
- 1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
- 1.2.2 Novantrone (Mitoxantrone)
- 1.2.3 Gilenya (Fingolimod, Fty720)
- 1.2.4 Aubagio (Teriflunomide)
- 1.2.5 Tecfidera (Dimethyl Fumarate)
- 1.2.6 Firategrast (Sb683699, T-0047)
- 1.2.7 Siponimod (Baf312)
- 1.2.8 Others
- 1.3 Downstream Application of Multiple Sclerosis (MS) Drugs
 - 1.3.1 RRMS
 - 1.3.2 SPMS
 - 1.3.3 PPMS
 - 1.3.4 PRMS
- 1.4 Development History of Multiple Sclerosis (MS) Drugs
- 1.5 Market Status and Trend of Multiple Sclerosis (MS) Drugs 2013-2023
- 1.5.1 Global Multiple Sclerosis (MS) Drugs Market Status and Trend 2013-2023
- 1.5.2 Regional Multiple Sclerosis (MS) Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Multiple Sclerosis (MS) Drugs 2013-2017
- 2.2 Production Market of Multiple Sclerosis (MS) Drugs by Regions
 - 2.2.1 Production Volume of Multiple Sclerosis (MS) Drugs by Regions
 - 2.2.2 Production Value of Multiple Sclerosis (MS) Drugs by Regions
- 2.3 Demand Market of Multiple Sclerosis (MS) Drugs by Regions
- 2.4 Production and Demand Status of Multiple Sclerosis (MS) Drugs by Regions
- 2.4.1 Production and Demand Status of Multiple Sclerosis (MS) Drugs by Regions 2013-2017
- 2.4.2 Import and Export Status of Multiple Sclerosis (MS) Drugs by Regions 2013-2017

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES



- 3.1 Production Volume of Multiple Sclerosis (MS) Drugs by Types
- 3.2 Production Value of Multiple Sclerosis (MS) Drugs by Types
- 3.3 Market Forecast of Multiple Sclerosis (MS) Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry
- 4.2 Market Forecast of Multiple Sclerosis (MS) Drugs by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

- 5.1 Global Economy Situation and Trend Overview
- 5.2 Multiple Sclerosis (MS) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 MULTIPLE SCLEROSIS (MS) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

- 6.1 Production Volume of Multiple Sclerosis (MS) Drugs by Major Manufacturers
- 6.2 Production Value of Multiple Sclerosis (MS) Drugs by Major Manufacturers
- 6.3 Basic Information of Multiple Sclerosis (MS) Drugs by Major Manufacturers
- 6.3.1 Headquarters Location and Established Time of Multiple Sclerosis (MS) Drugs Major Manufacturer
- 6.3.2 Employees and Revenue Level of Multiple Sclerosis (MS) Drugs Major Manufacturer
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch

CHAPTER 7 MULTIPLE SCLEROSIS (MS) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 Bayer AG
 - 7.1.1 Company profile
 - 7.1.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.1.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Bayer AG



- 7.2 Bayhill Therapeutics
 - 7.2.1 Company profile
 - 7.2.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.2.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Bayhill Therapeutics
- 7.3 Biogen Idec
 - 7.3.1 Company profile
 - 7.3.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.3.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec
- 7.4 Cinnagen
 - 7.4.1 Company profile
 - 7.4.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.4.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Cinnagen
- 7.5 Daiichi Sankyo
 - 7.5.1 Company profile
 - 7.5.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.5.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo
- 7.6 Eli Lilly
 - 7.6.1 Company profile
 - 7.6.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.6.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly
- 7.7 Fast Forward Llc
 - 7.7.1 Company profile
 - 7.7.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.7.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Fast Forward Llc
- 7.8 Antisense Therapeutics
 - 7.8.1 Company profile
 - 7.8.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.8.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Antisense Therapeutics
- 7.9 Apitope
 - 7.9.1 Company profile
 - 7.9.2 Representative Multiple Sclerosis (MS) Drugs Product
 - 7.9.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of



Apitope

- 7.10 Five Prime Therapeutics
 - 7.10.1 Company profile
 - 7.10.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.10.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Five Prime Therapeutics
- 7.11 Genmab
 - 7.11.1 Company profile
 - 7.11.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.11.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Genmab
- 7.12 Artielle Immunotherapeutics
- 7.12.1 Company profile
- 7.12.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.12.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Artielle Immunotherapeutics
- 7.13 Genzyme
 - 7.13.1 Company profile
 - 7.13.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.13.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Genzyme
- 7.14 Glaxosmithkline
 - 7.14.1 Company profile
 - 7.14.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.14.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Glaxosmithkline
- 7.15 Gw Pharmaceuticals
 - 7.15.1 Company profile
- 7.15.2 Representative Multiple Sclerosis (MS) Drugs Product
- 7.15.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Gw Pharmaceuticals
- 7.16 Innate Immunotherapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

- 8.1 Industry Chain of Multiple Sclerosis (MS) Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis



CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

- 9.1 Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
- 9.2 Raw Materials Cost Analysis of Multiple Sclerosis (MS) Drugs
- 9.3 Labor Cost Analysis of Multiple Sclerosis (MS) Drugs
- 9.4 Manufacturing Expenses Analysis of Multiple Sclerosis (MS) Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Multiple Sclerosis (MS) Drugs-Global Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/M5E21103709MEN.html

Price: US\$ 2,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M5E21103709MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970